Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT02377245
Enrolling by invitation Observational

Juvenile Inflammatory Rheumatism (JIR) Cohorte

NCT02377245 · tracked via the Priya Life Science France tracker
Sponsor
Michaël Hofer
Phase
Observational
Started
2014-01
Last updated
2023-06-15

Condition(s) studied

Arthritis, Juvenile Rheumatoid

Study summary

The investigators created a cohort of patients with juvenile inflammatory rheumatisms with the purpose to follow them prospectively, and investigate the tolerance and efficacy of immunosuppresive and biological agents.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients with juvenile inflammatory diseases * Age at onset up to 18 years old * Consent according national codes of ethics and current laws Exclusion Criteria: * Non-consent from patients and/or legal representative

Primary outcome measure(s)

  • Number of severe and very severe adverse event as a mesure of safety and tolerability — 10 years
  • Number of treatments prescribed off label — 10 Years
  • Length in months of drug survival in patient treated with at least two consecutive biological agents — 10 Years

Trial sites (45)

FacilityCityRegionStatus
Hôpital Reine Fabiola Brussels Belgium
CHU Charleroi Charleroi Belgium
UZ Leuven Leuven Belgium
CHC Liège Liège Belgium
CHR Citadelle Liège Belgium
CHU Belfort Belfort France
CHRU Besançon Besançon France
Hôpital Pellegrin enfants Bordeaux France
CHRU Brest Brest France
Hôpital Femme Mère Enfant Bron France
CHU Clermont-Ferrand Clermont-Ferrand France
CHU de Grenoble Grenoble France
Hôpital Bicêtre Le Kremlin-Bicêtre France
CHRU Lille Lille France
Hôpital Nord Marseille Marseille France
CHU Arnaud de Villeneuve Montpellier France
Centre hospitalier de Mulhouse Mulhouse France
CHU Nantes Nantes France
Nice CHU - Lenval Nice France
CHU Nimes Nîmes France
Hôpital necker Enfants Malade Paris France
Hôpital Robert Debré Paris France
Hôpital Tenon Paris France
CHU Reims Reims France
CHU Rennes Rennes France
CHU St-Etienne Saint-Etienne France
Hôpital de Hautepierre Strasbourg France
Hôpital des enfants Toulouse France
CHU Tours Tours France
Hôpital André Mignot Versailles France
University Hospital Muenster Münster Germany
Hôpital Ibnou Rochd Casablanca Morocco
CHUV Lausanne Canton of Vaud
Kantonsspital Aarau Aarau Switzerland
Kinderspital Basel Basel Switzerland
Universitäts-Augenklinik Basel Basel Switzerland
Ospedale Regionale di Bellinzona e valli Bellinzona Switzerland
Kantonspital Graubunden Chur Switzerland
Hôpital Ophtalmique Lausanne Switzerland
Kinderspital Luzern Lucerne Switzerland

+ 5 more sites — see the full list on the official registry below.

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02377245 on ClinicalTrials.gov ↗ ← All trials in France